Pharma owners warned of Brexit effect on TMs

Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Brexit: The waiting game

1 October 2019 As lawyers and industry prepare for a possible no-deal Brexit, the uncertainty surrounding its impact is palpable, as LSIPR’s Saman Javed discovers.

Big Pharma

UK life sciences bodies submit concerns over ‘no deal’ Brexit

12 November 2018 Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Pharma owners warned of Brexit effect on TMs

More on this story

Editor's picks

Editor's picks

More features